A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation
← catalyst calendarSponsored by Verastem, Inc. (industry) · VSTM — their whole pipeline →. With European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
225estimated
Sites
47
Countries
Belgium, Canada, France +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-12-21 | actual | When the study began enrolling |
| Primary completion | 2024-11-15 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2020-11-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-01-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Low Grade Ovarian Serous Adenocarcinoma
- Ovarian Cancer
Interventions
- Drug: avutometinib (VS-6766)
- Drug: avutometinib (VS-6766) and defactinib — also filed as avutometinib (VS-6766) and VS-6063
Primary outcomes
what the primary-completion date above is the date OFPart A: Determine optimal regimen of avutometinib (VS-6766) monotherapy or in combination with defactinib
measured From start of treatment to confirmation of response; 24 weeks
Part B: To determine the efficacy of the optimal regimen identified from Part A
measured From start of treatment to confirmation of response; 24 weeks
Part C: To evaluate additional efficacy parameters for the optimal regimen identified in Part A
measured From start of treatment to confirmation of response; 24 weeks
Part D:To evaluate additional efficacy parameters for a lower dose of avutometinib in combination with defactinib
measured From start of treatment to confirmation of response; 24 weeks
Publications
- PMID 40644648 — linked by the registry
- PMID 38493021 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · VSTM's whole pipeline · Catalyst calendar · Every registered study · What changed